MMIT Introduces Launch Coverage Analytics

MMIT’s latest product release, Launch Coverage Analytics, is now available. Launch Coverage Analytics builds on MMIT’s industry-leading Analytics platform with a targeted solution for pharma companies that are in the first six months of a drug launch and are looking for a way to track key access changes on a weekly basis.

Tracking access in real-time is critical to early brand success, and the first six months of a drug launch represents the most important period for tracking payer uptake. Knowing the percentage of payers with favorable coverage (including details on step therapy and prior authorization requirements) and the impact of major changes to coverage helps pharma leaders measure the success of their contracting strategy. The ability to drive prescription volume is directly tied to the level of favorable brand coverage (the No. 1 predictive indicator for bottom line performance).

Launch Coverage Analytics replaces the need for a pharma company to use Analytics data to create their own custom dashboard or hire an expensive third-party consultant to build custom views. Instead, MMIT provides pharma companies with an out-of-the-box, intuitive dashboard to track weekly patient access performance across geographies, payer channels and specific accounts. Market Access teams can now quickly and easily communicate weekly access changes to leadership and across their organization.

For more information, contact marketing@mmitnetwork.com.

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Another-Immunotherapy-Indication-Will-Be-Withdrawn.jpg
November 18

FDA Grants Interchangeable Status to Humira Biosimilar, but Certain Factors May Hamper Its, Other Adalimumabs’ Uptake

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-drug-benefits-OptumRx-Spotlights-Two-Drugs-That-Treat-Rare-Liver-Diseases.jpg
November 18

Oncologists Show Interest in Prescribing New CML STAMP Inhibitor Scemblix

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-RADAR-on-Drug-Benefits-Eli-Lilly-Pounces-on-Flailing-Aduhelm-With-Competing-Drug.jpg
November 18

Eli Lilly Pounces on Flailing Aduhelm With Competing Drug

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today